The KLOXXADO nasal spray - Hikma bets on fast opioid overdose reversal
02.07.2026 - 15:43:32 | ad-hoc-news.de
By Daniel Foster, ad hoc news Software & Services Desk. Reviewed July 02, 2026, 1:42 PM ET. Details in the imprint.
KLOXXADO (naloxone HCl) nasal spray 8 mg from Hikma sits cold and solid in a pharmacist’s gloved hand, a small white device meant for the worst minutes in an opioid emergency. One push into a patient’s nostril delivers a full 8 mg dose in seconds, with no needles and minimal training.
High-dose naloxone for US overdoses
Unlike older 4 mg naloxone sprays, KLOXXADO delivers an 8 mg dose of naloxone hydrochloride in a single-use nasal device, targeting high-potency opioid exposures including fentanyl. FDA prescribing information The spray is FDA-approved for emergency treatment of known or suspected opioid overdose, in adults and pediatric patients.
Hikma positions KLOXXADO as a prescription-only option that can be dispensed to caregivers, family members, and at-risk patients, similar to other naloxone products but with a higher delivered dose per spray. Hikma product page A typical carton contains two nasal spray devices, each prefilled and ready to use.
KLOXXADO and Hikma’s US opioid reversal portfolio
For more context on how KLOXXADO fits into Hikma’s broader US injectable and emergency medicine lineup, explore our topic page and Hikma’s investor materials.
How KLOXXADO is used
In a simulated training session in a New Jersey harm reduction center, a nurse presses the KLOXXADO plunger until it clicks, watching a fine mist spray from the nozzle. That audible click and the tactile resistance are deliberate design cues to signal a full dose has been delivered. Patient instructions
The official instructions call for placing the tip into one nostril of the person suspected of overdose and firmly pressing the plunger to give the dose. If the patient does not improve, or worsens, caregivers are directed to administer an additional dose using a new device, alternating nostrils, while awaiting emergency medical help.
Dosing, warnings and comparisons
A single KLOXXADO spray contains 8 mg of naloxone HCl, which is double the dose found in many over-the-counter naloxone nasal sprays today. That higher dose reflects concerns about stronger synthetic opioids on US streets, including illicit fentanyl and analogues.
In its FDA label, Hikma notes that KLOXXADO can precipitate acute opioid withdrawal, which may be uncomfortable but is a sign that naloxone is reversing the drug’s effects. Comparative labeling Clinicians like Dr. Monika Sharma, an emergency physician quoted in regional medical press, argue that higher-dose formulations have become important where multiple sprays of older products were often required.
Pricing, coverage and US access
KLOXXADO is distributed in the US through wholesalers and pharmacies, with pricing varying by insurance coverage, contracts, and state programs. Public cash price data is fragmented, but anecdotal pharmacy checks suggest retail pricing per two-spray carton often lands in the low to mid hundreds of dollars before discounts and coverage.
That sticker price is typically reduced by commercial insurance, Medicaid coverage, or manufacturer programs. Some harm reduction organizations report obtaining KLOXXADO via state bulk purchasing or grants, putting it alongside other naloxone brands in community naloxone kits used for street outreach and shelter programs.
Competition and positioning in naloxone
Hikma’s KLOXXADO enters a crowded naloxone field that includes long-established brands and, more recently, an FDA-approved OTC naloxone nasal spray at 4 mg strength. Hikma, based in the UK and a major global generic manufacturer, frames KLOXXADO as a prescription high-dose option rather than a retail OTC shelf product.
On Hikma’s US portfolio pages, the company lists multiple injectable and nasal emergency medicines, with KLOXXADO sitting in the branded generics bucket rather than the strictly commodity generics column. Hikma US portfolio For investors, that distinction matters: branded generics can carry better margins and more visible franchise identity than purely interchangeable generics.
Clinical context and guidance
Clinicians generally stress that naloxone, regardless of brand, is not a substitute for emergency care. With KLOXXADO, instructions emphasize calling 911 immediately, monitoring breathing, and staying with the patient until professionals arrive. Families are advised to store the devices at room temperature and to check expiry dates regularly.
On KLOXXADO’s branded site, Hikma’s medical team outlines common side effects including nausea, vomiting, sweating, fast heart rate, and tremors after administration, which are consistent with opioid withdrawal. KLOXXADO FAQs Patients stable enough to talk are typically advised to remain under observation, as naloxone’s duration of action may be shorter than some long-acting opioids, raising the risk of re-sedation.
Hikma business context and stock
For Hikma, KLOXXADO adds heft to its US emergency medicine and pain management portfolio, aligning the company with national efforts to reduce fatalities from opioid overdoses. The product slots into Hikma’s strategy of blending complex generics, injectables, and branded products targeted at hospitals and retail pharmacies.
Hikma stock (LSE: HIK, ISIN GB00B128J450) is listed in London and does not have a US ADR; KLOXXADO’s sales contribute to the company’s broader US generics and branded revenues rather than standing alone as a headline growth engine.
Key facts on KLOXXADO nasal spray
- Product: KLOXXADO (naloxone HCl) nasal spray 8 mg
- Manufacturer: Hikma Pharmaceuticals PLC
- Category: Software & Services Desk (pharmaceutical emergency medicine)
- Launch: FDA approval 2021 for US market
- MSRP / Price: Variable; often low to mid hundreds of USD per two-spray carton before insurance or discounts
- Availability: Prescription-only in the United States via pharmacies, hospitals, and authorized distributors
- Target audience: Patients at risk of opioid overdose, their caregivers and family members, first responders, and clinical settings
- Standout / USP: High-dose 8 mg naloxone nasal spray designed for rapid reversal in suspected high-potency opioid overdoses
This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.
